TP53 and carcinoma: Three of these five carcinoma patients demonstrated a mutation in the tumor suppressor TP53 (R273C, R248Q, R196*) while two patients had five aberrations in cell cycle regulation including CDKN2A/B loss, and CCND1 and CCNE1 amplifications.